Compare Axogen Inc (AXGN) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs Nuwellis Inc — how do they compare? Axogen Inc trades at $38.69 (market cap $2.06B), while Nuwellis Inc trades at $3.22 (market cap $1.17M). The key difference: Axogen Inc is far larger — about 1760.7× Nuwellis Inc's market cap, and Axogen Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | NUWE | |
|---|---|---|
Market Cap | $2.06B | $1.17M |
Sector | Technology | Technology |
52-Week High | $46.19 | $558.26 |
52-Week Low | $11.28 | $2.80 |
Enterprise Value | $1.98B | -$636.97K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
